Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials

Main Article Content

Andrew Blauvelt
Oregon Medical Research Center

Linda Stein Gold
Henry Ford Health System

Melinda Gooderham
Skin Centre for Dermatology

Bruce Strober
Yale University School of Medicine

Andreas Pinter
University Hospital Frankfurt

Jose-Manuel Carrascosa
Hospital Universitari Germans Trias I Pujol, UAB, IGTP, Badalona

Paolo Gisondi
University of Verona

Jonathan Bleier
Veramed and UCB Pharma

Cynthia Madden
UCB Pharma

Delphine Deherder
UCB Pharma

Natalie Nunez Gomez
UCB Pharma

Richard B Warren
Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical Research Centre, The University of Manchester

Keywords

bimekizumab, psoriasis, biologic, pooled data, efficacy, safety, phase 3, clinical trial

Abstract

N/A

References

1. Reich K et al. Lancet 2021;397:487–98, NCT03370133

2. Gordon KB et al. Lancet 2021;397:475–86, NCT03410992

3. Warren RB et al. N Engl J Med 2021;385:130–41, NCT03412747

4. Reich K et al. N Engl J Med 2021;385:142–52, NCT03536884

5. BE BRIGHT: clinicaltrials.gov/ct2/show/NCT03598790; 6Gordon KB et al. JAMA Dermatol 2022; published online ahead of print

Article Sidebar

Poster PDF
Published
Nov 16, 2022
DOI https://doi.org/10.25251/skin.6.supp.67

Article Details

How to Cite
[1]
Blauvelt, A., Stein Gold, L., Gooderham, M., Strober, B., Pinter, A., Carrascosa, J.-M., Gisondi, P., Bleier, J., Madden, C., Deherder, D., Gomez, N.N. and Warren, R.B. 2022. Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials. SKIN The Journal of Cutaneous Medicine. 6, 6 (Nov. 2022), s67. DOI:https://doi.org/10.25251/skin.6.supp.67.
Issue
Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Section
Poster Presentations from FC22 Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>